Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

de Bono J. S., Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., ...More

LANCET, vol.376, no.9747, pp.1147-1154, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 376 Issue: 9747
  • Publication Date: 2010
  • Doi Number: 10.1016/s0140-6736(10)61389-x
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1147-1154
  • Istanbul University Affiliated: Yes


Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment.